Trial reportArthritis care & research2026
Digital Behavioral Therapy Improves Outcome in Patients With Axial Spondyloarthritis and Persistent Pain: A Randomized Controlled Trial.
Trial report in Arthritis care & research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Article
- Psychosocial dimensions of pain in axial spondyloarthritis: Construct validity and responsiveness of the multidimensional pain inventory (MPI).Therapeutic advances in musculoskeletal disease · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
objectiveAxial spondyloarthritis (axSpA) is often associated with persistent pain despite effective anti-inflammatory treatment. Digital health applications (DHAs) provide innovative approaches to address multidimensional aspects of persistent pain through psychological and behavioral strategies. The aim of this study was to assess the impact of a DHA using acceptance and commitment therapy (ACT) on disease outcomes, including the West Haven-Yale Multidimensional Pain Inventory (MPI), in patients with axSpA experiencing persistent pain despite stable pharmacological therapy.
methodsThis unblinded, multicentric, randomized controlled trial compared an intervention group (IG) receiving the ACT app with a standard of care (SOC) group. The ACT app provided behavioral therapy. The primary outcome was MPI pain-related life interference; secondary outcomes included pain severity, affective distress, and other patient-reported outcomes after 12 weeks. Linear models estimating the effect of the ACT app on the change of MPI pain-related life interference and affective distress were calculated.
resultsA total of 136 patients were randomized to IG (n = 73) with the ACT app and SOC (n = 63) without the ACT app. In the IG, 44 actively used the ACT app. All lessons in the ACT app were completed by 19 IG patients (43%). Baseline characteristics, including MPI scores, were comparable between groups. IG showed a reduction in pain-related life interference as well as in other outcomes. The improvements in pain-related life interference (β with -0.36, 95% confidence interval [CI]: -0.73 to 0.01) and affective distress related to the disease (-0.4; 95% CI -0.84 to 0.03) were greater compared with SOC.
conclusionThe ACT app demonstrated a meaningful reduction in pain-related life interference, supporting that DHAs might become a complementary tool in managing pain for patients with axSpA. Studies about improving adherence to DHAs are warranted.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.